Renovacor (NYSE:RCOR) Downgraded by LADENBURG THALM/SH SH to “Neutral”

LADENBURG THALM/SH SH cut shares of Renovacor (NYSE:RCORGet Rating) from a buy rating to a neutral rating in a research report sent to investors on Tuesday, The Fly reports.

RCOR has been the subject of several other reports. Robert W. Baird started coverage on shares of Renovacor in a research report on Monday, September 12th. They set an outperform rating for the company. BTIG Research assumed coverage on Renovacor in a report on Wednesday, September 14th. They set a buy rating on the stock. Finally, Lifesci Capital reaffirmed an outperform rating on shares of Renovacor in a report on Thursday, June 16th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $21.00.

Renovacor Price Performance

RCOR opened at $2.18 on Tuesday. The company’s 50 day simple moving average is $1.86 and its 200-day simple moving average is $2.65. Renovacor has a one year low of $1.34 and a one year high of $10.47. The stock has a market capitalization of $37.64 million, a P/E ratio of -2.99 and a beta of 0.09.

Institutional Investors Weigh In On Renovacor

An institutional investor recently bought a new position in Renovacor stock. State Street Corp purchased a new position in Renovacor, Inc. (NYSE:RCORGet Rating) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,829 shares of the company’s stock, valued at approximately $50,000. State Street Corp owned 0.07% of Renovacor as of its most recent SEC filing. Hedge funds and other institutional investors own 45.84% of the company’s stock.

Renovacor Company Profile

(Get Rating)

Renovacor, Inc, a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM).

Further Reading

The Fly logo

Analyst Recommendations for Renovacor (NYSE:RCOR)

Receive News & Ratings for Renovacor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovacor and related companies with's FREE daily email newsletter.